FAQ: Annovis Bio's $6 Million Registered Direct Offering

What is the main announcement in this content?

Annovis Bio Inc. (NYSE: ANVS) has closed a registered direct offering of 4 million shares of common stock (or pre-funded warrants) at $1.50 per share, generating approximately $6 million in gross proceeds before fees and expenses.

How much money did Annovis Bio raise in this offering?

The company raised gross proceeds totaling approximately $6 million before fees and expenses through the sale of 4 million shares at $1.50 per share.

What will Annovis Bio use the proceeds for?

The net proceeds from the offering are intended for working capital and general corporate purposes to support the company’s operations and development activities.

Who managed the registered direct offering?

H.C. Wainwright & Co. served as the exclusive placement agent for this registered direct offering.

What type of company is Annovis Bio?

Annovis Bio is a late-stage clinical drug platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s disease, headquartered in Malvern, Pennsylvania.

Where can I find more detailed information about this offering?

The full press release is available at https://ibn.fm/p55Nb, and additional company information can be found at www.annovisbio.com.

How can investors stay updated on Annovis Bio news?

The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS, and investors can follow the company on LinkedIn, YouTube, and X.

What is the significance of this funding for Annovis Bio?

This $6 million capital infusion provides working capital to support the company’s ongoing development of innovative therapies for neurodegenerative diseases, helping advance their clinical programs for Alzheimer’s and Parkinson’s patients.